Study of new drug FID-022 for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new study drug called FID-022 for people with pancreatic cancer. It is a first-in-human study, meaning it is the first time this drug is being tested in people, and researchers want to see if it is safe and how it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with pancreatic cancer (or doctors strongly suspect it)
- Your treatment plan involves or will likely involve chemotherapy or other systemic therapy
- You can eat and drink by mouth (no feeding tube or IV nutrition)
- You do not have fluid buildup in your belly or other serious health problems that are not controlled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
This trial tests a new drug combination for people whose pancreatic cancer has grown after their first treatment. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests EF-009, a study medicine, in adults with pancreatic cancer that doctors consider “borderline resectable” or “unresectable.” The goal is to see how safe it is and how well it works for this situation.
This trial tests a new drug called onvansertib combined with standard chemotherapy (NALIRIFOX) as the first treatment for advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to see if adding onvansertib helps shrink tumors or slow the cancer better than chemo alone.
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.